Araris Biotech is the latest addition to the Redalpine portfolio (Redalpine Capital IV). We are excited to lead the CHF 2.5m Seed round, with the participation of VI Partners and Schroder Adveq.
The ETH Zurich and Paul Scherrer Institute (PSI) spin-off is pioneering a technology enabling fast and precise development of Antibody-Drug Conjugates (ADCs). ADCs are powerful combinations of specific antibodies, delivering highly potent drugs to the desired tissue. A common use case is the targeted treatment of tumour cells.
Araris is developing ground-breaking technology for the all-important linkage between the antibodies and the drug. Their linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need for prior antibody engineering. In addition, their innovative approach allows for more stable ADCs for higher efficacy and lower side effect risk. As a consequence, Araris has the potential to set new benchmarks in terms of ADC development, analysis and performance.
“We have been in touch with Philipp, the founder and CEO of Araris, for quite some time now. We have always been impressed by the linker technology and the potential it has in the ADC market. It’s fantastic to partner with the Araris team to help bring their technology to market“, remarks Michael Sidler, founding partner at Redalpine.
For additional information, check out the Araris website.
Image: Araris founding Team Dragan Grabulovski, Isabella Attinger-Toller, Philipp Spycher